BofA raised the firm’s price target on Ionis Pharmaceuticals to $68 from $67 and keeps a Buy rating on the shares after the company presented new ION582 data from the HALOS Phase 1/2 study in Angelman syndrome, or AS. The data suggest ION582 has therapeutic potential in AS, says the firm, which raised its view of the program odds of success to 40% from 30%, driving its increased price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharma’s ION582 shows positive Phase 1/2 results in Angelman syndrome
- Ionis Pharmaceuticals completes enrollment in trial of zilganers in AxD
- Ionis Pharmaceuticals price target raised to $67 from $64 at BofA
- Ionis Pharmaceuticals assumed at Buy from Underperform at Jefferies
- Ionis Pharmaceuticals price target raised to $53 from $50 at Stifel